ARDUAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARDUAN (ARDUAN).
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
| Metabolism | Hepatic (approximately 90%), primarily via CYP3A4; renal elimination of unchanged drug and metabolites. |
| Excretion | Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%) |
| Half-life | Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment |
| Protein binding | Approximately 30% bound to albumin |
| Volume of Distribution | Approximately 0.3 L/kg (range 0.2-0.4 L/kg); consistent with extracellular fluid distribution |
| Bioavailability | Intravenous only; oral bioavailability negligible due to quaternary ammonium structure |
| Onset of Action | Intravenous: 1-3 minutes for intubation doses (0.06-0.08 mg/kg) |
| Duration of Action | Clinical duration (time to 25% twitch recovery): 30-60 minutes after intubating dose; prolonged with higher doses or renal impairment |
| Action Class | Skeletal muscle relaxant- Peripherally acting |
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-30 mL/min: reduce initial dose by 50%; GFR <10 mL/min: avoid use or use with extreme caution |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use |
| Pediatric use | Neonates and infants: initial IV 0.05 mg/kg; children: initial IV 0.06-0.08 mg/kg, maintenance 0.005-0.01 mg/kg every 30-60 min |
| Geriatric use | Initiate at lower end of dosing range (e.g., 0.06 mg/kg) due to decreased clearance; monitor for prolonged blockade |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARDUAN (ARDUAN).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not established. Consider risks to infant; caution advised. |
| Teratogenic Risk | Pregnancy Category C. No adequate human studies. In animal studies, fetal growth retardation and skeletal anomalies observed at doses 2-3 times human dose. Risk in first trimester unknown; second and third trimester may cause neonatal respiratory depression and hypotonia. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. Facilities and equipment for endotracheal intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available.
| Serious Effects |
Hypersensitivity to pipecuronium or any component; known allergy to bromides (contains bromide ion).
| Precautions | Risk of prolonged neuromuscular blockade in patients with renal impairment, hepatic disease, or electrolyte disturbances; may cause histamine release leading to bronchospasm or hypotension; caution in patients with neuromuscular diseases; use with appropriate monitoring and reversal agents. |
| Food/Dietary | No known food interactions. Maintain standard preoperative fasting guidelines as per anesthesia protocol. |
Loading safety data…
| Monitor uterine tone, fetal heart rate, and maternal vital signs. Assess for signs of acidosis or electrolyte imbalances. Neonatal monitoring for respiratory depression and muscle weakness. |
| Fertility Effects | No data on human fertility effects. In animal studies, no impairment of fertility observed at clinically relevant doses. |
| Clinical Pearls | Arduan (pipecuronium) is a long-acting non-depolarizing neuromuscular blocker. Use with caution in renal impairment as it is primarily renally excreted; prolonged paralysis may occur. Reversal with neostigmine is effective but may be slower. Avoid in patients with known hypersensitivity to bromides. Monitor train-of-four ratio for recovery. Onset is slower than vecuronium; consider for long procedures. |
| Patient Advice | This medication causes temporary paralysis and you will be on a breathing machine. · You will not be able to move or breathe on your own while the drug is active. · You will be given sedation and pain medication to keep you comfortable. · The effects will wear off after surgery, and you will regain muscle function gradually. · Inform your doctor if you have kidney problems, as this may prolong the effect. |